Europäische Leitlinien (S1) für die Verwendung von hoch dosierten intravenösen Immunglobulinen in der Dermatologie

Translated title of the contribution: European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology

Eva Hadaschik, Rüdiger Eming, Lars E. French, Giampiero Girolomoni, Michael Hertl, Stephen Jolles, Sarolta Karpati, Kerstin Steinbrink, Georg Stingl, Beatrix Volc-Platzer, Detlef Zillikens, Alexander Enk

Research output: Contribution to journalArticle

Abstract

Background and objectives: Treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe cases, the use of immunoglobulin is not generally based on data from randomized controlled trials usually required for evidence-based medicine. Since the indications for the use of IVIg are rare, it is unlikely that such studies will be available in the foreseeable future. Because first-line use is limited by the high costs of IVIg, the first clinical guidelines on the use of IVIg in dermatological conditions were established in 2008 and renewed in 2011. Methods: The European guidelines presented here were prepared by a panel of experts nominated by the European Dermatology Forum (EDF) and European Academy of Dermatology and Venereology (EADV). The guidelines were developed to update the indications for treatment currently considered effective and to summarize the evidence for the use of IVIg in dermatological autoimmune diseases and TEN. Results and conclusion: The current guidelines represent consensual expert opinions and definitions on the use of IVIg reflecting current published evidence and are intended to serve as a decision-making tool for the use of IVIg in dermatological diseases.

Translated title of the contributionEuropean Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology
Original languageGerman
Pages (from-to)542-552
Number of pages11
JournalHautarzt
Volume71
Issue number7
DOIs
Publication statusPublished - Jul 1 2020

Keywords

  • Autoimmune diseases
  • Decision tree
  • Dosing
  • Expert consensus
  • Therapy

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology'. Together they form a unique fingerprint.

  • Cite this

    Hadaschik, E., Eming, R., French, L. E., Girolomoni, G., Hertl, M., Jolles, S., Karpati, S., Steinbrink, K., Stingl, G., Volc-Platzer, B., Zillikens, D., & Enk, A. (2020). Europäische Leitlinien (S1) für die Verwendung von hoch dosierten intravenösen Immunglobulinen in der Dermatologie. Hautarzt, 71(7), 542-552. https://doi.org/10.1007/s00105-020-04610-6